870521-30-5

Basic information

• Product Name: 2-ISOPROXYPYRIDINE-5-BORONIC ACID
• Synonyms: 2-ISOPROXYPYRIDINE-5-BORONIC ACID;6-Isopropoxypyridine-3-boronic acid;[6-(propan-2-yloxy)pyridin-3-yl]boronic acid;6-Isopropoxypyridin-3-boronic acid;(6-Isopropoxy-3-pyridyl)boronic acid;2-Isopropoxy-5-pyridineboronic acid;6-Isoproxypyridine-3-boronic acid
• CAS NO: 870521-30-5
• Molecular Formula: C8H12BNO3
• Molecular Weight: 181
• Product Categories: boric acid|ether
• Mol File: 870521-30-5.mol

Chemical Properties

• Boiling Point: 325.498 °C at 760 mmHg
• Flash Point: 150.656 °C
• Appearance: /Solid
• Density: 1.16
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 7.08±0.18(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2-ISOPROXYPYRIDINE-5-BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ISOPROXYPYRIDINE-5-BORONIC ACID(870521-30-5)
• EPA Substance Registry System: 2-ISOPROXYPYRIDINE-5-BORONIC ACID(870521-30-5)

Safety Data

• Hazardous Substances Data: 870521-30-5(Hazardous Substances Data)

Usage

InChI:InChI=1S/C8H12BNO3/c1-6(2)13-8-4-3-7(5-10-8)9(11)12/h3-6,11-12H,1-2H3

Upstream product

• 870521-31-6 5-bromo-2-isopropoxy-pyridine 
• 7732-18-5 water 
• 73183-34-3 bis(pinacol)diborane 
• 5419-55-6 Triisopropyl borate 

Downstream Products

• 870637-91-5 C₂₉H₂₇F₃N₂O₇ 

Relevant articles and documents

PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR

The present invention discloses a series of pyrazolopyrimidine derivatives and use thereof in preparing a medicament for treating a disease related to PI3K, and in particular, discloses a derivative compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof.

Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor δ agonists

The discovery, synthesis, and optimization of compound 1 from a high-throughput screening hit to highly potent and selective peroxisome proliferator-activated receptor δ (PPARδ) agonists are reported. The synthesis and structure-activity relationship in this series are described in detail. On the basis of a general schematic PPAR pharmacophore model, scaffold 1 was divided into headgroup, linker, and tailgroup and successively optimized for PPAR activation using in vitro PPAR transactivation assays. A (2-methylphenoxy)acetic acid headgroup, a flexible linker, and a five-membered heteroaromatic center ring with two hydrophobic aryl substituents were required for efficient and selective PPARδ activation. The fine-tuning of these aryl substituents led to an array of highly potent and selective compounds such as compound 38c, displaying an excellent pharmacokinetic profile in mouse. In an in vivo acute dosing model, selected members of this array were shown to induce the expression of pyruvate dehydrogenase kinase-4 (PDK4) and uncoupling protein-3 (UCP3), genes that are known to be involved in energy homeostasis and regulated by PPARδ in skeletal muscle.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.

INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided a compound of formula: (I), wherein X, R1, R2, R3, R4, R5 and R6 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or required, and particularly in the treatment of inflammation.